Efficacy of Once-Daily Olopatadine 0.2% Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1% Ophthalmic Solution for the Treatment of Ocular Itching Induced by Conjunctival Allergen Challenge

REFERENCES

• Abelson M B, Smith L, Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocular Surface. 2003; 1: 127–149
   PubMedGoogle Scholar
• Phipatanakul W. Allergic rhinoconjunctivitis: Epidemiology. Immunol Allergy Clin North Am 2005; 25: 263–281
   PubMed Web of Science ®Google Scholar
• Abelson M B, George M, Garafalo C. Differential diagnosis of ocular allergic disorders [published correction appears in Ann Allergy 1993;70:192]. Ann Allergy. 1993; 70: 95–109
   PubMedGoogle Scholar
• Abelson M B, Allansmith M R. Histamine in the eye. Immunology and Immunopathology of the Eye, A Silverstein, G O'Connor. Masson Publishing, New York 1979; 362–364
   Google Scholar
• Yanni J, Stephens D, Miller S, et al. The in vitro and in vivo ocular pharmacology of olopatadine (al-4943a), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996; 12: 389–400
   PubMed Web of Science ®Google Scholar
• Brockman H L, Momsen M M, Knudtson J R, et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm. 2003; 11: 247–268
   PubMed Web of Science ®Google Scholar
• Artal M N, Luna J D, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol Scan 2000; 78: 63–65
   Google Scholar
• Katelaris C H, Cipriandi G, Missotten L, et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodidum 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther. 2002; 24: 1561–1575
   PubMed Web of Science ®Google Scholar
• Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: A double-masked environmental study of patient preference. Curr Med Res Opin 2004; 20: 1167–1173
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Turner D, Gross R D. Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr Ther Res 2004; 65: 186–199
   PubMed Web of Science ®Google Scholar
• Abelson M B. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81: 211–218
   PubMed Web of Science ®Google Scholar
• Abelson M B, Gomes P J, Vogelson C T, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: A randomized, double-masked environmental study. Clin Ther. 2004; 26: 1237–1248
   PubMed Web of Science ®Google Scholar
• Vogelson C, Abelson M, Pasquine T, et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 2004; 25: 69–75
   PubMed Web of Science ®Google Scholar
• Lichtenstein S, Vogelson C, Wells D, et al. Olopatadine is safe and well-tolerated in adults and children as young as three years of age. Presented at Western Society of Allergy, Asthma & Immunology Annual Meeting, Wailea, HI, Jan, 19–232003
   Google Scholar
• Abelson M, Chambers W, Smith L. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990; 108: 84–88
   PubMed Web of Science ®Google Scholar
• Lanier R, Finegold I, D'Arienzo P, Granet D, Epstein A B, Ledgerwood G. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004; 20: 2644–2651
   Web of Science ®Google Scholar
• Abelson M B, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthal 1998; 125: 797–804
   PubMed Web of Science ®Google Scholar
• Olopatadine H Cl. 0.1% Summary Basis of Approval. 1997, FDA NDA 020688. April 11
   Google Scholar
• Richter A, Anton S E, Koch P, Dennett S L. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307–2335
   PubMed Web of Science ®Google Scholar
• Yanni J M, Miller S T, Gamache D A, Spellman J M, Xu S, Sharif N A. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Annal Allergy Asthma Immunol 1997; 79: 541–545
   PubMed Web of Science ®Google Scholar
• Edwards M R, Pasquine T, Gross R D, Robertson S M. Frequency of treatment-related ocular adverse events associated with olopatadine 0.2% (Pataday™) in clinical trials. Presented at Western Society of Allergy, Asthma & Immunology Annual Meeting, Wailea, HI, Jan, 232007
   Google Scholar
• Lichtenstein S J, Pasquine T A, Edwards M R, et al. Safety and tolerability of olopatadine 0.2% in children and adolescents. J Ocular Pharmcol Ther 2007; 23: 366–371
   PubMed Web of Science ®Google Scholar
• Giger R, Pasche P, Cheseauz C, et al. Comparison of once- versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis. Eur Arch Otorhinolaryngol 2003; 260: 135–140
   PubMed Web of Science ®Google Scholar
• Scoper S V, Berdy G J, Lichtenstein S J, et al. Physician assessment, patient perception, and safety of once-a-day olopatadine in treating allergic conjunctivitis. Presented at American College of Allergy, Asthma & Immunology, Philadelphia, PA, Nov., 11–122006
   Google Scholar
• Claxton A J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310
   PubMed Web of Science ®Google Scholar
• Kardas P. The DIACOM study (effect of dosing frequency of oral antidiabetic agents on the compliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005; 7: 722–728
   PubMed Web of Science ®Google Scholar
• Granger A L, Fehnel S E, Hogue S L, Bennett L, Edin H M. An assessment of patient preference and adherence to treatment with Wellbutrin SR: A web-based survey. J Affect Disord 2006; 90: 217–221
   PubMed Web of Science ®Google Scholar
• McDonald H P, Garg A X, Haynes R B. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868–2879
   PubMed Web of Science ®Google Scholar
• Guest J F, Davie A M, Ruiz F J, Greener M J. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005; 14: 88–98
   PubMedGoogle Scholar
• Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther 1999; 21: 138–147
   PubMed Web of Science ®Google Scholar